Using Venture Capital to Improve Global Health
| Firm Name | Adjuvant Capital |
| Investment Thesis / Tagline | Using Venture Capital to Improve Global Health |
| Primary Office Locations | New York (headquarters), San Francisco, Zürich |
| Year Founded | 2018 |
| Team Size (Partners/Employees) | 14 employees total (10+ listed on team page: Glenn Rockman, Jenny Yip, Philippe Dro, Mark Sullivan, Curt LaBelle, Kabeer Aziz, Michael Chang, Joshua Adeoye, Lilly deSouza Burr, Dimple Sahni plus others) |
| Investment Stage | Late-stage clinical (Phase II+) life sciences; clinical trials investment for neglected diseases (vaccines, therapeutics, diagnostics for neglected infectious diseases) |
| Founders | Glenn Rockman and Kabeer Aziz (Co-Founders & Partners) |
| Fund Entity Name | ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND |
| Primary Contact Email | yanatos@adjuvantcapital.com |
| Assets Under Management | $300 million (raised February 18, 2021, announced February 24, 2021) |
| Typical Investment Size | $10-25 million per company |
| Investment Focus Areas | Neglected infectious diseases; maternal, newborn, and child health; reproductive and adolescent health; nutrition; vaccines, therapeutics, and diagnostics |
| Number of Portfolio Companies | 15+ portfolio companies (LimmaTech Biologics, Memo Therapeutics, Curevo Vaccine, Antiva Biosciences, Pulmocide, Excision BioTherapeutics, Frontier Nutrition, VitriVax, MinervaX, Evofem, Quantoom, LakeShore Biopharma, ChromaCode, 54gene, Codagenix, AN2 Therapeutics, Themis, InDevR, X-Vax) |